PDF Archive

Easily share your PDF documents with your contacts, on the Web and Social Networks.

Share a file Manage my documents Convert Recover PDF Search Help Contact



cvfile 0023229 .pdf


Original filename: cvfile_0023229.pdf
Title: CURRICULUM VITAE
Author: 원자력 병원 내과 박연희

This PDF 1.5 document has been generated by Word용 Acrobat PDFMaker 10.1 / Adobe PDF Library 10.0, and has been sent on pdf-archive.com on 05/07/2015 at 18:23, from IP address 78.157.x.x. The current document download page has been viewed 3115 times.
File size: 136 KB (6 pages).
Privacy: public file




Download original PDF file









Document preview


CURRICULUM VITAE
(Last Updated : 2013-04-16)
NAME IN FULL - YEON HEE PARK, M.D.
ADDRESS - DEPARTMENT OF HEMATOLOGY AND ONCOLOGY
SAMSUNG MEDICAL CENTER
SUNGKYUNKWAN UNVERSITY, SCHOOL OF MEDICINE
81, IRWON-RO, GANGNAM-GU
SEOUL, 135-710, KOREA
DESCRIPTION
EDUCATION - 1984 - 1987 SUH MOON GIRL'S HIGH SCHOOL
1987 - 1993 M.D. DEGREE FROM EWHA WOMEN'S UNIVERSITY
COLLEGE OF MEDICINE, SEOUL, KOREA
1996 - 1998 MASTER'S DEGREE FROM KYUNGHEE UNIVERSITY
GRADUATED SCHOOL, SEOUL, KOREA
1999 - 2000 DOCTOR'S DEGREE FROM KYUNGHEE UNIVERSITY
GRADUATED SCHOOL, SEOUL, KOREA
PROFESSIONAL LICENSURE - M.D , 49292, KOREA
CAREER - 1993 - 1994 INTERNSHIP IN KOREA CANCER CENTER HOSPITAL
1994 - 1998 RESIDENCY OF INTERNAL MEDICINE
KOREA CANCER CENTER HOSPITAL
1998 - 1999 CLINICAL FELLOWSHIP
DIVISION OF HEMATOLOGY AND ONCOLOGY
DEPARTMENT OF INTERNAL MEDICINE
KOREA CANCER CENTER HOSPITAL
2000 - 2001 STAFF
DIVISION OF HEMATOLOGY AND ONCOLOGY
DEPARTMENT OF INTERNAL MEDICINE
SEOUL ADVENTIST HOSPITAL
2001- 2006 STAFF
DIVISION OF HEMATOLOGY AND ONCOLOGY
DEPARTMENT OF INTERNAL MEDICINE
KOREA CANCER CENTER HOSPITAL
2006. 3 – 2006. 9 POSTDOC FELLOWSHIP

UCSD CANCER CENTER
SAN DIEGO, CA
2006. 9 – 2007. 12 POSTDOC FELLOWSHIP
SYDNEY KIMMEL CANCER CENTER
SAN DIEGO, CA
2008. 1 – 2008. 2 CLINICAL ASSITANT PROFESSOR
DEPARTMENT OF HEMATOLOGY AND ONCOLOGY
SAMSUNG MEDICAL CENTER
SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE
SEOUL, KOREA
2008. 3 – present ASSOCIATE PROFESSOR
DEPARTMENT OF HEMATOLOGY AND ONCOLOGY
SAMSUNG MEDICAL CENTER
SUNGKYUNKWAN UNIVERSITY, SCHOOL OF MEDICINE
SEOUL, KOREA
MEMBERSHIP – AMERICAN SOCIETY OF CLINICAL ONCOLOGY
AMERICAN SOCIETY OF HEMATOLOGY
THE KOREAN MEDICAL ASSOCIATION
THE KOREAN ASSOCIATION OF INTERNAL MEDICINE
THE KOREAN CANCER ASSOCIATION
THE KOREAN SOCIETY FOR HOSPICE & PALLIATIVE CARE
THE KOREAN SOCIETY OF HEMATOLOGY
KOREAN CANCER STUDY GROUP
KOREAN ASSOCIATION FOR CLINICAL ONCOLOGY
CLINICAL TRIAL EXPERIENCE
- A Phase III, randomized, Double-blind, Placebo-Controlled, Multicenter study to evaluate the
efficacy and safety of Bevacizumab, and Associcated Biomarkers, in combination with Paclitaxel
compared with Paclitaxel plus Placebo as 1st line Treatment of patients with HER2-Negative
Metastatic Breast cancer, sponsored by Roche, 2013, Principal investigator [GO25632]
- A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients with
Metastatic or Recurrent Breast Cancer, sponsored by Nippon Kayaku, 2013, Principal investigator
[NK105]
- A Phase 3 Open-label, Randomized, Multicenter study of NKTR-102 versus Treatment of
physician’s choice(TPC) in patients with locally recurrent or metastatic breast cancer previously
treated with an anthracycline, a taxane, and capecitabine, sponsored by Nektar, 2013,
sub-investigator [BEACON]
- A Phase 2 Randomized Trial of the Combination of Ridaforolimus and Exmestane, Compared to
Ridaforolimus, Dalotuzumab and Exmestane in High Proliferation Estrogen Receptor Positive
Breast Cancer Patients. sponsored by MSD, 2012, Principal investigator[MK8669-064]

-2-

- Randomized phase II study of lapatinib plus vinorelbine versus vinorelbine in patients with HER2
positive metastatic breast cancer progressed after lapatinib and trastuzumab treatment, IIT, 2012,
Sub-investigator [LV]
- A randomized, double-blind, placebo controlled, phase II study of BKM120 plus paclitaxel in
patients with HER2 negative inoperable locally advanced or metastatic breast cancer, with or
without PI3K pathway activation, sponsored by Novartis, 2012, Sub-investigator[BELLE4]
- An open label, phase II trial of afatinib with or without vinorelbine for the treatment of
HER2-overexpressing Inflammatory Breast Cancer, sponsored by Boehringer Ingelheim, 2012,
Sub-investigator[BIBW1200.89]
- A phase III prospective, 2-cohort, non-randomized, multi-center, multinational, open label study
to assess the safety of assisted-and self-administered subcutaneous trastuzumab ad adjuvant
therapy in patients with operable HER2-positive early breast cancer, sponsored by ROCHE, 2012,
sub-investigator[SafeHer]
- A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus
trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant
therapy in patients with operable HER2-positive primary breast cancer, sponsored by Roche, 2011,
Sub-investigator[APHINITY]
- Phase III multicenter Randomized Open-label study of irinotecan plus CapEcitabine versus
capEcitabine in patients previously treateD with anthracycline and taxane for HER2 negative
metastatic breast cancer, IIT, 2011, Principal investigator [PROCEED]
- A phase III randomized, multicenter, 2-arm, open-label trial to evaluate the efficacy of T-DM1
compared with treatment of physician’s choice in patients with HER2-positive metastatic breast
cancer who have received at least 2 prior regimens of HER2-directed therapy, sponsored by Roche,
2011, Sub-investigator[THERESA]
- A Phase III trial to compare the safety and efficacy of lapatinib plus trastuzumab plus an
aromatase inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as 1st-line
therapy in postmenopausal subjects with hormone receptor positive, HER2-positive metastatic
breast cancer (MBC) who have received trastuzumab and endocrine therapy in the neoadjuvant
and/or adjuvant setting, sponsored by GSK, 2011, Sub-investigator[EGF114299]
- A randomized, Double-Bline, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as
Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence,
sponsored by Amgen, 2011, sub-investigator[D-CARE]
- A phase II trial of NEoadjuvant bevAcizumab, docetaxel and carboplatin for Triple negative
breast cancer(NEAT trial). 2011, sub-investigator
- A multi-center, randomized phase II, 3-arm, open-lavel study of goserelin plus fulvestrant versus
goserelin plus anastrozole versus goserelin alone for hormone receptor-positive, tamoxifen
pretreated, premenopausal women with recurrent or metastatic breast cancer.(FLAG) 2010,
sub-investigator
- Phase 1/2, open-label, randomized study of the safety, efficacy, and pharmacokinetics of
Letrozole plus PD 0332991 (Oral CDK 4/6 inhibitor) and Letrozole single agent for the 1st line
treatment of ER positive, HER2 negative advanced Breast cancer in postmenopausal women,
sponsored by Pfizer, 2010, Sub-investigator [A5481003]
- A two-part,adaptive,randomized trial of ridaforolimus in combination with dalotuzumab
coapared to exemestane or compared to ridaforolimus or dalotuzumab monotherapy in estrogen
receptor positive breast cancer patients, sponsored by MSD, 2010, Principal investigator

-3-

- An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and
vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior
trastuzumab treatment, sponsored by Boehringer Ingelheim, 2010, Sub-investigator[BIBW1200.75]
- A phase Ⅲ clinical trial comparing Trastuzumab given concurrently with Radiation Therapy
and Radiation Therapy alone for women with HER-2 positive Ductal Carcinoma In situ resected by
Lumpectomy, sponsored by NSABP, 2010, Sub-investigator[NSABP B-43]
-A randomized, 3 arm, multicenter, phase III studyto evaluate the efficacy and the safety of T-DM1
combined with pertuzumab or T-DM1 combined with pertuzumab-placebo (blinded for
pertuzumab), versus the combination of trastuzumab plus taxane, sponsored by Roche, 2010,
Sub-investigator [Marianne]
-A multicenter, multinational phase II study to assess the clinical safety and feasibility of T-DM1
sequentially with anthracycline-based chemotherapy, as adjuvant or neoadjuvant therapy for
patients with early stage HER2-positive breast cancer, sponsored by Roche, 2010, Sub-investigator
[TDM4874g][BO22857]
- A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus
Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative,
Unresectable, Locally-Recurrent or Metastatic Breast Cancer, sponsored by ICON, 2010, Principal
investigator [TRIO-012 study]
-A phase 2, randomised, double-blind, placebo-controlled,multi-centre study to assess the efficacy
and safety of AZD8931 in combination with Anastrozole,compared to anastrozole alone, in
post-menopausal women with hormone receptor-positive, endocrine therapy-naïve,
locally-advanced or metastatic breast cancer, sponsored by AstraZeneca, Principal investigator,
2010 [MINT]
- A randomized double-blind placebo-controlled tiral of neratinib (HKI-272) after trastuzumab in
women with early-stage HER-2/neu overexpressed/amplified breast cancer, sponsored by Wyeth,
2009, Sub-investigator
- A phase III, randomized, open-label study to compare pharmocokinetics, efficacy and safety of
subcutaneous (SC) trastuzumab with intravenous (IV) trastuzumab administered in women with
HER2 positive early breast cancer (EBC), sponsored by Roche, 2009, Sub- investigator [HannaH]
- A phase 1/2, open-label study of neratinib (HKI-272) in combination with capecitabine in subjects
with solid tumors and erbB-2 positive metastatic or locally advanced breast cancer, sponsored by
Wyeth, 2009, sub-investigator [3144A1-2206-WW]
- A randomized, multicenter, phase III open-label study of the efficacy and safety of
trastuzumab-MCC-DM1 vs. capecitabine + lapatinib in patients with HER2-positive locally
advanced or metastatic breast cancer who have received prior tratuzumab-based therapy,
sponsored by Roche, 2009, Sub-investigator [EMILIA]
- A double-blind, Randomised, Parallel Phase I/IIb study to Evaluate Initial Safety and Efficacy,
Comparative Pharmacokinetics and Immunogenicity for CT-P6 and Herceptin in Metastatic breast
cancer, sponsored by Cell trion, 2009, Sub-investigator [Compare study]
- A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in
combination with trastuzumab and paclitaxel, as first line therapy in women with HER2 positive
locally advanced or metastatic breast cancer, sponsored by Norvatis, 2009, Sub-investigator
[BOLERO-1: Breast cancer trials of OraL EveROlimus]
- A phase III randomized study of capecitabine as adjuvant chemotherapy versus observation in
breast cancer with pathologic residual tumors after preoperative chemotherapy, sponsored by
JBCRG, KBCSG, KCSG, 2009, Sub-investigator [CREATE-X: Capecitabine for Residual cancer as
Adjuvant ThErapy – X]

-4-

- A phase 3, randomized, open-label study of neratinib versus lapatinib plus capecitabine for the
treatment of erbB-2-positive locally advanced or metastatic breast cancer, sponsored by Wyeth,
2009, Sub-investigator [3144A2-3003-WW]
- An open-label, phase Ib continuation study of lapatinib monotherapy or lapatinib in combination
with other anti-cancer treatment in patients with solid tumors, sponsored by GSK, 2009,
Sub-investigator [EGF111767]
- An open-label, single sequence study to examine the effects of esomeprazole on the
pharmacokinetics of orally administered lapatinib in subjects with metastatic ErbB2 positive breast
cancer, sponsored by GSK, 2009, Sub-investigator [EGF109275]
- A partially-blind phase III randomized trial of fulvestrant (Faslodex) with or without concomitant
anastrozole (Arimidex) compared with exemestane in postmenopausal women with ER+ve locally
advanced/metastatic breast cancer following progressin on non-steoidal aromatase inhibitors,
sponsored by AstraZeneca, 2008, Sub-investigator [SoFEA: Study of Faslodex with or without
concomitant Arimidex vs Exemestane following progressin on non-steroidal Aromatase inhibitors]
- A multicenter phase III randomized trial of adjuvant therapy for patients with HER2-postive
node-positive or high risk node-negative breast cancer comparing chemotherapy plus trastuzumab
with chemotherapy plus trastuzumab plus bevacizumab, sponsored by Roche, 2008,
Sub-investigator [BETH: Bevacizumab with Trastuzumab Adjuvant Therapy in HER2+ Breast
Cancer]
- A phase III, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy
and safety of pertuzumab +trastuzumab + docetaxel vs. placebo +trastuzumab + docetaxel in
previously untreated HER2-positive metastatic breast cancer, sponsored by Roche, 2008.
Sub-investigator [CLEOPATRA: Clinical Evaluation of Pertuzumab and Trastuzumab]
- A randomized, multicenter, open-label, phase III study of neoadjuvant lapatinib, trastuzumab,
and their combination plus paclitaxel in women with HER2/ErbB2 ositive primary breast cancer,
sponsored by GSK, 2008. Sub-investigator [Neo-ALTTO: Neo- Adjuvnat Lapatinib and/or
Trastuzumab Treatment Optimisation study]
- An international multicenter open-label 2-arm phase III trial of adjuvant bevacizumab in triple
negative breast cancer, sponsored by Roche, 2008. Sub-investigator [BEATRICE: Bevacizumab
adjuvant therapy in triple-negative breast cancer]
- A randomized, multicenter, multinational phase II study on trastuzumab plus docetaxel versus
trastuzumab plus docetaxel plus pertuzumab versus trastuzumab plus pertuzumab in patients with
locally advanced, inflammatory or early stage HER2 positive breast cancer, sponsored by Roche,
2008. Sub-investigator [Neo-Sphere]
- Predictive methods for detecting early cardiotoxicity in patients with breast cancer who receive
anthracycline-containing chemotherapy or trastuzumab, IIT, 2008. Sub-investigator
- A randomized, multicentre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their
sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer,
sponsored by GSK, 2008. Sub-investigator [ALTTO: Adjuvnat Lapatinib and/or Trastuzumab
Treatment Optimisation study]
- Phase II trial of TS-2 in combination with oxaliplatin in patients with recurrent or metastatic
breast cancer previously treated with or resistant to an anthracycline and taxane chemotherapy
(TORCH), IIT, 2008. Sub- investigator
- A phase III, multicenter, randomized trial of maintenance versus intermittent chemotherapy after
achieving clinical response in patients with metastatic or recurrent breast cancer who received 6
cycles of gemcitabine plus paclitaxel (GP) as first-line chemotherapy, IIT, 2008. Sub-investigator

-5-

TRAINING ON ICH/GCP
I received GCP training at tens of investigator meetings related with clinical trials listed above. I
have also received GCP training through IRB.
I successfully completed the online training CITI on Oct 28 2010, on Dec 14 2012.

I hereby certify the above statement to be true and correct in every details
YEON HEE PARK, M.D., PH.D.

-6-


Related documents


cvfile 0023229
2016010408 10 48reena nair cv 2016
cvfile 0023228
protocols list clinical research program
v15n4s57revisiting
darrel e drachenberg cv dedd updated aug 2013 most recent


Related keywords